BioSpace News Archive

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today the pricing of an underwritten public offering of 15,243,903 shares of its common stock, at a price to the public of $2.05 per share.

Webcast registration link appears below Andreea Porcelli, CEO of Swiss Growth Forum, will be a co-presenter on the webcast in her separate capacity as a sponsor of the proposed SPAC Andreea Porcelli and Jaguar CEO Lisa Conte interviewed again on Innovators with Jane King

Integrity Laboratories announced today, the launch of the first commercially available quantitative index to accompany positive COVID-19 specimen resulted through their EUA approved platform.

Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a life sciences company developing biotechnologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming, today announced that it has entered into a securities purchase agreement in connection with a financing with an institutional investor (the “Investor”).

OS Therapies, a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat and cure Osteosarcoma (OS) and other deadly cancers in kids and adults, today announced the approval of the OST-HER2 PhIIb clinical trial in recurred, resected Osteosarcoma.

CARBAGLU is First and Only FDA-Approved Medication for Hyperammonemia Associated with These Rare Conditions

Investis Digital, a leading global digital communications company announced that they have entered into a strategic partnership with eClinicalHealth (Clinpal™).

Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced filing of a patent disclosing enhancement of natural killer cell and T cell activity by StemVacs after treatment with homotaurine, a safe blood-brain barrier permeable GABA A-R-specific agonist

Echosens, a high-technology company offering the FibroScan family of products, announces its partnership with Gastrologix to provide independent GI practices in its group purchasing organization (GPO) with the enhanced services of FibroScan, a non-invasive device that helps to assess liver health

Phoenix Children’s recently achieved accreditation as an Adult Congenital Heart Disease Comprehensive Care Center from the Adult Congenital Heart Association, a nationwide organization dedicated to education, advocacy and research to improve the lives of those born with heart defects.